Clinical trial NCT00113204: Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
Official title: A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Multiple Myeloma
Keywords: Multiple myeloma
Relapsed
Relapsed refractory
Hematologic cancer
hematologic disease
plasma cells
Lead sponsor: Infinity Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2005-06-07
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504.

Detailed description: IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in regulating protein homeostasis. Hsp90 regulates the stability of key proteins (called "client proteins") and keeps them in the appropriate three dimensional shape so they can perform their cellular functions. In addition, many of the proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. Thus Hsp90, a single molecular target that is a central integrator of multiple pathways important to cancer, is an ideal novel target for oncologic therapy. Selective inhibition of Hsp90 will affect multiple downstream mechanisms to disrupt tumor growth and selectively kill cancer cells. The anti-neoplastic effects of Hsp90 inhibition have been demonstrated both in vitro and in vivo for a variety of different hematologic and solid tumors including multiple myeloma.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of relapsed or relapsed, refractory disease
* Age is greater or equal to 18 years at the time of signing the informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Ability to adhere to the study visit schedule and all protocol requirements
* Voluntarily sign an informed consent
* All baseline studies must be completed for determining eligibility within 21 days of study enrollment
* Women of child-bearing potential (WCBP) defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test prior to each cycle of treatment
* All WCBP and all sexually active male patients must agree to use adequate methods of birth control throughout the study

Exclusion Criteria:

* Disease specific treatment within the previous 3 weeks including use of chemotherapy that is known to be active or may be active against multiple myeloma
* Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor
* Participation in any investigational drug study within 3 weeks preceding start of treatment for conventional small molecule therapy or 4 weeks preceding the start of treatment for biologic or vaccine therapy; concurrent radiation therapy is not permitted
* Concomitant use of corticosteroids may not exceed prednisone 10 mg per day with the exception of pre-medication for transfusion of blood products and topical application
* Concurrent treatment with any agent that alters CYP3A activity (unless maintained on stable dose)
* Baseline QTc \>450
* NYHA class 3 or 4 congestive heart failure
* Left Bundle Branch Block
* Mycardial infarction or active ischemic heart disease within 6 months
* Grade 3 or greater peripheral neuropathy
* Renal insufficiency, serum creatinine \>2x upper limit of normal (ULN)
* Platelets \< 30,000 mm3 or refractory to transfusion and unable to be maintained \> 50,000 mm3
* AST and / or ALT \> 2.0x ULN
* ANC \<1,000 cells/mm3
* Hemoglobin \< 8.0 g/dL
* Presence of active infection or systemic use of antibiotics within 72 hours of treatment
* WCBP who are breast feeding
* Significant co-morbid condition or disease which in the judgment of the investigator would place the patient at undue risk or interfere with the study (e.g. cardiac disease such as acute coronary syndrome or unstable angina within 6 months, New York Heart Association (NYHA) class 2 or greater congestive heart failure (CHF), uncontrolled hypertension, arrhythmia requiring medication or mechanical control, chronic obstructive pulmonary disease (COPD), cirrhotic liver disease, or other conditions)

Primary outcomes:
measure: To determine the safety and maximum tolerated dose of IPI-504
timeFrame: Following 1 cycle of treatment
measure: Recommend a dose for subsequent studies of IPI-504
timeFrame: Once MTD is reached
Secondary outcomes:
measure: To examine the pharmacokinetic parameters of IPI-504
timeFrame: During first dose first cycle of IPI-504
measure: To evaluate the potential anti-tumor activity with standard markers of disease progression
timeFrame: 1 cycle of treatment
measure: To examine pharmacodynamic markers of biologic activity of IPI-504
timeFrame: Cycle 1 of treatment
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
state: Maryland
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Hackensack
country: United States
facility: Hackensack University Medical Center The David Jurist Research Center
state: New Jersey
city: New York
country: United States
facility: St. Vincent's Comprehensive Cancer Center
state: New York
Study officials:
affiliation: St. Vincent's Comprehensive Cancer Center
name: Sundar Jagannath, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hackensack Meridian Health
name: David S. Siegel, MD; Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center
name: Ivan Borrello, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dana-Farber Cancer Institute
name: Paul Richardson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002 Jan;2(1):3-24. doi: 10.1517/14712598.2.1.3.
citation: Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003 Feb;228(2):111-33. doi: 10.1177/153537020322800201.
citation: Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(4 Suppl):S55-61. doi: 10.1016/s1471-4914(02)02316-x.